4.5 Review

The neurobiology of skeletal pain

Journal

EUROPEAN JOURNAL OF NEUROSCIENCE
Volume 39, Issue 3, Pages 508-519

Publisher

WILEY-BLACKWELL
DOI: 10.1111/ejn.12462

Keywords

age; bone; cartilage; CRPS; marrow; nociceptor

Categories

Funding

  1. National Institutes of Health [NS023970, CA154550, CA157449]
  2. Abbott (Abbott Park, IL, USA)
  3. Adolor (Exton, PA, USA)
  4. Array Bio-pharma (Boulder, CO, USA)
  5. Johnson and Johnson (New Brunswick, NJ, USA)
  6. Pfizer (New York, NY, USA)
  7. Plexxikon (Berkeley, CA, USA)
  8. Roche (South San Francisco, CA, USA)

Ask authors/readers for more resources

Disorders of the skeleton are one of the most common causes of chronic pain and long-term physical disability in the world. Chronic skeletal pain is caused by a remarkably diverse group of conditions including trauma-induced fracture, osteoarthritis, osteoporosis, low back pain, orthopedic procedures, celiac disease, sickle cell disease and bone cancer. While these disorders are diverse, what they share in common is that when chronic skeletal pain occurs in these disorders, there are currently few therapies that can fully control the pain without significant unwanted side effects. In this review we focus on recent advances in our knowledge concerning the unique population of primary afferent sensory nerve fibers that innervate the skeleton, the nociceptive and neuropathic mechanisms that are involved in driving skeletal pain, and the neurochemical and structural changes that can occur in sensory and sympathetic nerve fibers and the CNS in chronic skeletal pain. We also discuss therapies targeting nerve growth factor or sclerostin for treating skeletal pain. These therapies have provided unique insight into the factors that drive skeletal pain and the structural decline that occurs in the aging skeleton. We conclude by discussing how these advances have changed our understanding and potentially the therapeutic options for treating and/or preventing chronic pain in the injured, diseased and aged skeleton.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available